Yu-Sheng Shu1, Wei Tao, Qian-Bing Miao, Ya-Bing Zhu, Yi-Feng Yang. 1. From the Department of Cardiothoracic Surgery (Y.-S.S., Y.-F.Y.), the Second Xiangya Hospital of Central South University, Changsha, Hunan; Department of Cardiothoracic Surgery (Y.-S.S., Q.-B.M.), Subei People's Hospital of Jiangsu Province, Yangzhou, Jiangsu; Department of Surgery (W.T.), Yangzhou East Hospital, Yangzhou, Jiangsu; and Department of Cardiothoracic Surgery (Y.-B.Z.), Hangzhou First People's Hospital, Hangzhou, Zhejiang, China.
Abstract
BACKGROUND: Inhibition of nuclear factor κB (NF-κB) activation is a well-know strategy to ameliorate ventilation-induced lung injury (VILI). Inhibitory κB kinase (IKK) plays a key role in the regulation of NF-κB activation. In this study, we determined whether inhibition of IKK by an IKK inhibitor exerts lung protection in a rat model of VILI. METHODS: Anesthetized and mechanically ventilated Sprague-Dawley rats were randomly assigned to a standard (tidal volume, 8 mL/kg) or high-tidal volume (tidal volume, 25 mL/kg) ventilation group. An IKK inhibitor (IKK 16) or vehicle was administrated 1 hour before the induction of VILI. All groups were ventilated and observed for 5 hours. RESULTS: High-pressure ventilation caused activation of NF-κB, increased pulmonary inflammatory mediator levels, lung edema, and impairment of gas exchange. The IKK inhibitor treatment significantly reduced these changes and increased interleukin 10 levels, heme oxygenase 1 activity, protein kinase B (Akt) phosphorylation levels, and nuclear amounts of nuclear factor E2-related factor 2 protein. CONCLUSION: IKK may be a therapeutic target for VILI. An IKK inhibitor, IKK 16, can dampen VILI in rats. The beneficial effect of the IKK 16 may be mediated through the inhibition of NF-κB pathway and up-regulation of nuclear factor E2-related factor 2-regulated heme oxygenase 1 through the activation of the phosphatidylinositol 3 kinase/Akt.
BACKGROUND: Inhibition of nuclear factor κB (NF-κB) activation is a well-know strategy to ameliorate ventilation-induced lung injury (VILI). Inhibitory κB kinase (IKK) plays a key role in the regulation of NF-κB activation. In this study, we determined whether inhibition of IKK by an IKK inhibitor exerts lung protection in a rat model of VILI. METHODS: Anesthetized and mechanically ventilated Sprague-Dawley rats were randomly assigned to a standard (tidal volume, 8 mL/kg) or high-tidal volume (tidal volume, 25 mL/kg) ventilation group. An IKK inhibitor (IKK 16) or vehicle was administrated 1 hour before the induction of VILI. All groups were ventilated and observed for 5 hours. RESULTS: High-pressure ventilation caused activation of NF-κB, increased pulmonary inflammatory mediator levels, lung edema, and impairment of gas exchange. The IKK inhibitor treatment significantly reduced these changes and increased interleukin 10 levels, heme oxygenase 1 activity, protein kinase B (Akt) phosphorylation levels, and nuclear amounts of nuclear factor E2-related factor 2 protein. CONCLUSION: IKK may be a therapeutic target for VILI. An IKK inhibitor, IKK 16, can dampen VILI in rats. The beneficial effect of the IKK 16 may be mediated through the inhibition of NF-κB pathway and up-regulation of nuclear factor E2-related factor 2-regulated heme oxygenase 1 through the activation of the phosphatidylinositol 3 kinase/Akt.
Authors: Alicia N Rizzo; Saad Sammani; Adilene E Esquinca; Jeffrey R Jacobson; Joe G N Garcia; Eleftheria Letsiou; Steven M Dudek Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-10-02 Impact factor: 5.464
Authors: Regina Sordi; Fausto Chiazza; Florence L Johnson; Nimesh S A Patel; Karim Brohi; Massimo Collino; Christoph Thiemermann Journal: Mol Med Date: 2015-06-18 Impact factor: 6.354
Authors: Jianmin Chen; Julius E Kieswich; Fausto Chiazza; Amie J Moyes; Thomas Gobbetti; Gareth S D Purvis; Daniela C F Salvatori; Nimesh S A Patel; Mauro Perretti; Adrian J Hobbs; Massimo Collino; Muhammad M Yaqoob; Christoph Thiemermann Journal: J Am Soc Nephrol Date: 2016-05-06 Impact factor: 10.121
Authors: Norman James Galbraith; James Burton; Mathew Brady Ekman; Joseph Kenney; Samuel Patterson Walker; Stephen Manek; Campbell Bishop; Jane Victoria Carter; Sarah Appel Gardner; Hiram C Polk Journal: PLoS One Date: 2017-09-14 Impact factor: 3.240